Covid-19 Research

Commentary

Limitations of Current Treatment of Alzheimer’s Disease and Proposed Plan to Improve it

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Commentary
Subject Medicine Group
OCLC JBRES Record
Kedar N Prasad*
Issue: Volume5-Issue9
Pages: 1116-1121
Received: 2024-08-25
Accepted: 2024-09-08
Published: 2024-09-11

Abstract

FullText HTML FullText PDF DOI: 10.37871/jbres1998 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2024 Prasad KN. Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Prasad KN. Limitations of Current Treatment of Alzheimer’s Disease and Proposed Plan to Improve it. J Biomed Res Environ Sci. 2024 Sept 11; 5(9): 1116-1121. doi: 10.37871/jbres1998, Article ID: JBRES1998, Available at: https://www.jelsciences. com/articles/jbres1998.pdf

Subject area(s)

AlzheimersNeurology

References

  1. Prasad KN. A micronutrient mixture with collagen peptides, probiotics, cannabidiol, and diet may reduce aging, and development and progression of age-related alzheimer's disease, and improve its treatment. Mech Ageing Dev. 2023 Mar;210:111757. doi: 10.1016/j.mad.2022.111757. Epub 2022 Nov 29. PMID: 36460123.
  2. Prasad KN. Simultaneous activation of Nrf2 and elevation of antioxidant compounds for reducing oxidative stress and chronic inflammation in human Alzheimer's disease. Mech Ageing Dev. 2016 Jan;153:41-7. doi: 10.1016/j.mad.2016.01.002. Epub 2016 Jan 23. PMID: 26811881.
  3. Prasad KN, Bondy SC. Inhibition of early upstream events in prodromal Alzheimer's disease by use of targeted antioxidants. Curr Aging Sci. 2014;7(2):77-90. doi: 10.2174/1874609807666140804115633. PMID: 25101711.
  4. Cui H, Kong Y, Zhang H. Oxidative stress, mitochondrial dysfunction, and aging. J Signal Transduct. 2012;2012:646354. doi: 10.1155/2012/646354. Epub 2011 Oct 2. PMID: 21977319; PMCID: PMC3184498.
  5. Misrani A, Tabassum S, Yang L. Mitochondrial Dysfunction and Oxidative Stress in Alzheimer's Disease. Front Aging Neurosci. 2021 Feb 18;13:617588. doi: 10.3389/fnagi.2021.617588. PMID: 33679375; PMCID: PMC7930231.
  6. Pajares M, Cuadrado A, Engedal N, Jirsova Z, Cahova M. The Role of Free Radicals in Autophagy Regulation: Implications for Ageing. Oxid Med Cell Longev. 2018 Feb 26;2018:2450748. doi: 10.1155/2018/2450748. PMID: 29682156; PMCID: PMC5846360.
  7. Heshmati J, Morvaridzadeh M, Maroufizadeh S, Akbari A, Yavari M, Amirinejad A, Maleki-Hajiagha A, Sepidarkish M. Omega-3 fatty acids supplementation and oxidative stress parameters: A systematic review and meta-analysis of clinical trials. Pharmacol Res. 2019 Nov;149:104462. doi: 10.1016/j.phrs.2019.104462. Epub 2019 Sep 26. PMID: 31563611.
  8. Cole GM, Ma QL, Frautschy SA. Omega-3 fatty acids and dementia. Prostaglandins Leukot Essent Fatty Acids. 2009 Aug-Sep;81(2-3):213-21. doi: 10.1016/j.plefa.2009.05.015. Epub 2009 Jun 12. PMID: 19523795; PMCID: PMC4019002.
  9. Misonou H, Morishima-Kawashima M, Ihara Y. Oxidative stress induces intracellular accumulation of amyloid beta-protein (Abeta) in human neuroblastoma cells. Biochemistry. 2000 Jun 13;39(23):6951-9. doi: 10.1021/bi000169p. PMID: 10841777.
  10. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001 Apr;81(2):741-66. doi: 10.1152/physrev.2001.81.2.741. PMID: 11274343.
  11. Yankner BA, Mesulam MM. Seminars in medicine of the Beth Israel Hospital, Boston. beta-Amyloid and the pathogenesis of Alzheimer's disease. N Engl J Med. 1991 Dec 26;325(26):1849-57. doi: 10.1056/NEJM199112263252605. PMID: 1961223.
  12. Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, Villemagne VL, Aisen P, Vendruscolo M, Iwatsubo T, Masters CL, Cho M, Lannfelt L, Cummings JL, Vergallo A. The Amyloid-β Pathway in Alzheimer's Disease. Mol Psychiatry. 2021 Oct;26(10):5481-5503. doi: 10.1038/s41380-021-01249-0. Epub 2021 Aug 30. PMID: 34456336; PMCID: PMC8758495.
  13. Liu Y, Chen Y, Fukui K. Oxidative stress induces tau hyperphosphorylation via MARK activation in neuroblastoma N1E-115 cells. J Clin Biochem Nutr. 2023 Jul;73(1):24-33. doi: 10.3164/jcbn.22-39. Epub 2023 May 16. PMID: 37534088; PMCID: PMC10390814.
  14. Melov S, Adlard PA, Morten K, Johnson F, Golden TR, Hinerfeld D, Schilling B, Mavros C, Masters CL, Volitakis I, Li QX, Laughton K, Hubbard A, Cherny RA, Gibson B, Bush AI. Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS One. 2007 Jun 20;2(6):e536. doi: 10.1371/journal.pone.0000536. PMID: 17579710; PMCID: PMC1888726.
  15. Dooley M, Lamb HM. Donepezil: a review of its use in Alzheimer's disease. Drugs Aging. 2000 Mar;16(3):199-226. doi: 10.2165/00002512-200016030-00005. PMID: 10803860.
  16. Sauder C, Allen LA, Baker E, Miller AC, Paul SM, Brannan SK. Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study. Transl Psychiatry. 2022 Nov 21;12(1):491. doi: 10.1038/s41398-022-02254-9. PMID: 36414626; PMCID: PMC9681874.
  17. Xin R, Chen Z, Fu J, Shen F, Zhu Q, Huang F. Xanomeline Protects Cortical Cells From Oxygen-Glucose Deprivation via Inhibiting Oxidative Stress and Apoptosis. Front Physiol. 2020 Jun 12;11:656. doi: 10.3389/fphys.2020.00656. PMID: 32595528; PMCID: PMC7303960.
  18. Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks J, Sims JR, Brys M, Apostolova LG, Salloway SP, Skovronsky DM. Donanemab in Early Alzheimer's Disease. N Engl J Med. 2021 May 6;384(18):1691-1704. doi: 10.1056/NEJMoa2100708. Epub 2021 Mar 13. PMID: 33720637.
  19. Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Bradley H, Rabe M, Koyama A, Reyderman L, Berry DA, Berry S, Gordon R, Kramer LD, Cummings JL. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther. 2021 Apr 17;13(1):80. doi: 10.1186/s13195-021-00813-8. Erratum in: Alzheimers Res Ther. 2022 May 21;14(1):70. doi: 10.1186/s13195-022-00995-9. PMID: 33865446; PMCID: PMC8053280.
  20. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29. PMID: 36449413.
  21. Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell. 1994 Jun 17;77(6):817-27. doi: 10.1016/0092-8674(94)90131-7. PMID: 8004671.
  22. Butterfield DA, Bush AI. Alzheimer's amyloid beta-peptide (1-42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide. Neurobiol Aging. 2004 May-Jun;25(5):563-8. doi: 10.1016/j.neurobiolaging.2003.12.027. PMID: 15172731.
  23. Li XL, Hu N, Tan MS, Yu JT, Tan L. Behavioral and psychological symptoms in Alzheimer's disease. Biomed Res Int. 2014;2014:927804. doi: 10.1155/2014/927804. Epub 2014 Jul 15. PMID: 25133184; PMCID: PMC4123596.
  24. Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol. 2012 May 7;3:73. doi: 10.3389/fneur.2012.00073. PMID: 22586419; PMCID: PMC3345875.
  25. Matsuda J, Namba T, Takabatake Y, Kimura T, Takahashi A, Yamamoto T, Minami S, Sakai S, Fujimura R, Kaimori JY, Matsui I, Hamano T, Fukushima Y, Matsui K, Soga T, Isaka Y. Antioxidant role of autophagy in maintaining the integrity of glomerular capillaries. Autophagy. 2018;14(1):53-65. doi: 10.1080/15548627.2017.1391428. PMID: 29130363; PMCID: PMC5846506.
  26. Behl C, Davis J, Cole GM, Schubert D. Vitamin E protects nerve cells from amyloid beta protein toxicity. Biochem Biophys Res Commun. 1992 Jul 31;186(2):944-50. doi: 10.1016/0006-291x(92)90837-b. PMID: 1497677.
  27. Butterfield DA, Koppal T, Subramaniam R, Yatin S. Vitamin E as an antioxidant/free radical scavenger against amyloid beta-peptide-induced oxidative stress in neocortical synaptosomal membranes and hippocampal neurons in culture: insights into Alzheimer's disease. Rev Neurosci. 1999;10(2):141-9. doi: 10.1515/revneuro.1999.10.2.141. PMID: 10658956.
  28. Prasad KN. Micronutrients in the prevention and improvement of the standard therapy for Alzheimer’s disease. Boca raton. Fl: CRC Press; 2019.
  29. Xiang S, Ji JL, Li S, Cao XP, Xu W, Tan L, Tan CC. Efficacy and Safety of Probiotics for the Treatment of Alzheimer's Disease, Mild Cognitive Impairment, and Parkinson's Disease: A Systematic Review and Meta-Analysis. Front Aging Neurosci. 2022 Feb 3;14:730036. doi: 10.3389/fnagi.2022.730036. PMID: 35185522; PMCID: PMC8851038.
  30. Tsai YC, Cheng LH, Liu YW, Jeng OJ, Lee YK. Gerobiotics: probiotics targeting fundamental aging processes. Biosci Microbiota Food Health. 2021;40(1):1-11. doi: 10.12938/bmfh.2020-026. Epub 2020 Oct 2. PMID: 33520563; PMCID: PMC7817508.
  31. Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, Mele MC. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. Microorganisms. 2019 Jan 10;7(1):14. doi: 10.3390/microorganisms7010014. PMID: 30634578; PMCID: PMC6351938.
  32. Ricard-Blum S. The collagen family. Cold Spring Harb Perspect Biol. 2011 Jan 1;3(1):a004978. doi: 10.1101/cshperspect.a004978. PMID: 21421911; PMCID: PMC3003457.
  33. Koizumi S, Inoue N, Sugihara F, Igase M. Effects of Collagen Hydrolysates on Human Brain Structure and Cognitive Function: A Pilot Clinical Study. Nutrients. 2019 Dec 23;12(1):50. doi: 10.3390/nu12010050. PMID: 31878021; PMCID: PMC7019356.
  34. Cheng JS, Dubal DB, Kim DH, Legleiter J, Cheng IH, Yu GQ, Tesseur I, Wyss-Coray T, Bonaldo P, Mucke L. Collagen VI protects neurons against Abeta toxicity. Nat Neurosci. 2009 Feb;12(2):119-21. doi: 10.1038/nn.2240. Epub 2009 Jan 4. PMID: 19122666; PMCID: PMC2812922.
  35. Chen JH, Hsu WC, Huang KF, Hung CH. Neuroprotective Effects of Collagen-Glycosaminoglycan Matrix Implantation following Surgical Brain Injury. Mediators Inflamm. 2019 Jan 27;2019:6848943. doi: 10.1155/2019/6848943. PMID: 30809107; PMCID: PMC6369484.
  36. Canhada S, Castro K, Perry IS, Luft VC. Omega-3 fatty acids' supplementation in Alzheimer's disease: A systematic review. Nutr Neurosci. 2018 Oct;21(8):529-538. doi: 10.1080/1028415X.2017.1321813. Epub 2017 May 3. PMID: 28466678.
  37. Cederholm T. Fish consumption and omega-3 fatty acid supplementation for prevention or treatment of cognitive decline, dementia or Alzheimer's disease in older adults - any news? Curr Opin Clin Nutr Metab Care. 2017 Mar;20(2):104-109. doi: 10.1097/MCO.0000000000000350. PMID: 27977429.
  38. Wei BZ, Li L, Dong CW, Tan CC, Alzheimer's Disease Neuroimaging I, Xu W. The Relationship of Omega-3 Fatty Acids with Dementia and Cognitive Decline: Evidence from Prospective Cohort Studies of Supplementation, Dietary Intake, and Blood Markers. Am J Clin Nutr. 2023;117(6):1096-109.
  39. Myoraku A, Klein G, Landau S, Tosun D; Alzheimer’s Disease Neuroimaging Initiative. Regional uptakes from early-frame amyloid PET and 18F-FDG PET scans are comparable independent of disease state. Eur J Hybrid Imaging. 2022 Jan 18;6(1):2. doi: 10.1186/s41824-021-00123-0. PMID: 35039928; PMCID: PMC8763988.
  40. Yu JH, Han K, Park S, Cho H, Lee DY, Kim JW, Seo JA, Kim SG, Baik SH, Park YG, Choi KM, Kim SM, Kim NH. Incidence and Risk Factors for Dementia in Type 2 Diabetes Mellitus: A Nationwide Population-Based Study in Korea. Diabetes Metab J. 2020 Feb;44(1):113-124. doi: 10.4093/dmj.2018.0216. Epub 2019 Nov 12. PMID: 31769236; PMCID: PMC7043975.
  41. Hayden MR. Type 2 Diabetes Mellitus Increases The Risk of Late-Onset Alzheimer's Disease: Ultrastructural Remodeling of the Neurovascular Unit and Diabetic Gliopathy. Brain Sci. 2019 Sep 29;9(10):262. doi: 10.3390/brainsci9100262. PMID: 31569571; PMCID: PMC6826500.
  42. Ferreira LSS, Fernandes CS, Vieira MNN, De Felice FG. Insulin Resistance in Alzheimer's Disease. Front Neurosci. 2018;12:830.
  43. Akbar M, Calderon F, Wen Z, Kim HY. Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):10858-63. doi: 10.1073/pnas.0502903102. Epub 2005 Jul 22. Erratum in: Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12997. PMID: 16040805; PMCID: PMC1182431.
  44. McManus K, Ash ET, Harper DG, Smith R, Gruber S, Forester B. Caring for behavior symptoms of dementia(CBD): A new investigation into cannabidiol for the treatment of anxiety and agitation in Alzheimer’s dementia. Am J Geriatr Psychiatry. 2021;29:S110-S1. doi: 10.1016/j.jagp.2024.01.172.
  45. Seeman P. Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Transl Psychiatry. 2016 Oct 18;6(10):e920. doi: 10.1038/tp.2016.195. PMID: 27754480; PMCID: PMC5315552.
  46. Linge R, Jiménez-Sánchez L, Campa L, Pilar-Cuéllar F, Vidal R, Pazos A, Adell A, Díaz Á. Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors. Neuropharmacology. 2016 Apr;103:16-26. doi: 10.1016/j.neuropharm.2015.12.017. Epub 2015 Dec 19. PMID: 26711860.
  47. Sales AJ, Fogaça MV, Sartim AG, Pereira VS, Wegener G, Guimarães FS, Joca SRL. Cannabidiol Induces Rapid and Sustained Antidepressant-Like Effects Through Increased BDNF Signaling and Synaptogenesis in the Prefrontal Cortex. Mol Neurobiol. 2019 Feb;56(2):1070-1081. doi: 10.1007/s12035-018-1143-4. Epub 2018 Jun 4. PMID: 29869197.
  48. Campos AC, Ferreira FR, Guimarães FS. Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors. J Psychiatr Res. 2012 Nov;46(11):1501-10. doi: 10.1016/j.jpsychires.2012.08.012. Epub 2012 Sep 11. PMID: 22979992.
  49. Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005;30(8):1037-43.
  50. Li H, Liu Y, Tian D, Tian L, Ju X, Qi L, Wang Y, Liang C. Overview of cannabidiol (CBD) and its analogues: Structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer's disease. Eur J Med Chem. 2020 Apr 15;192:112163. doi: 10.1016/j.ejmech.2020.112163. Epub 2020 Feb 22. PMID: 32109623.
  51. Xiong Y, Lim CS. Understanding the Modulatory Effects of Cannabidiol on Alzheimer's Disease. Brain Sci. 2021 Sep 14;11(9):1211. doi: 10.3390/brainsci11091211. PMID: 34573232; PMCID: PMC8472755.
  52. Watt G, Karl T. In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease. Front Pharmacol. 2017 Feb 3;8:20. doi: 10.3389/fphar.2017.00020. PMID: 28217094; PMCID: PMC5289988.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership